

## SEQUENCE LISTING

<110> WARATAH PHARMACEUTICALS, INC.  
CRUZ, Antonio

<120> METHODS AND COMPOSITIONS USING CD3 AGONISTS

<130> 179061-363728

<150> 60/584,635

<151> 2004-07-01

<160> 27

<170> PatentIn version 3.3

<210> 1

<211> 37

<212> PRT

<213> Artificial

<220>

<223> Synthesized peptide

<400> 1

His Asp Glu Phe Glu Arg His Ala Glu Gly Thr Phe Thr Ser Asp Val  
1 5 10 15

Ser Ser Tyr Leu Glu Gly Gln Ala Ala Lys Glu Phe Ile Ala Trp Leu  
20 25 30

Val Lys Gly Arg Gly  
35

<210> 2

<211> 36

<212> PRT

<213> Artificial

<220>

<223> Synthesized Peptide

<400> 2

His Asp Glu Phe Glu Arg His Ala Glu Gly Thr Phe Thr Ser Asp Val  
1 5 10 15

Ser Ser Tyr Leu Glu Gly Gln Ala Ala Lys Glu Phe Ile Ala Trp Leu  
20 25 30

Val Lys Gly Arg

35

<210> 3  
<211> 36  
<212> PRT  
<213> Artificial

<220>  
<223> Synthesized Peptide

<220>  
<221> MOD\_RES  
<222> (36)..(36)  
<223> AMIDATION

<400> 3

His Asp Glu Phe Glu Arg His Ala Glu Gly Thr Phe Thr Ser Asp Val  
1 5 10 15

Ser Ser Tyr Leu Glu Gly Gln Ala Ala Lys Glu Phe Ile Ala Trp Leu  
20 25 30

Val Lys Gly Arg  
35

<210> 4  
<211> 31  
<212> PRT  
<213> Artificial

<220>  
<223> Synthesized Peptide

<400> 4

His Ala Glu Gly Thr Phe Thr Ser Asp Val Ser Ser Tyr Leu Glu Gly  
1 5 10 15

Gln Ala Ala Lys Glu Phe Ile Ala Trp Leu Val Lys Gly Arg Gly  
20 25 30

<210> 5  
<211> 30  
<212> PRT  
<213> Artificial

<220>  
<223> Synthesized Peptide

<400> 5

His Ala Glu Gly Thr Phe Thr Ser Asp Val Ser Ser Tyr Leu Glu Gly  
1 5 10 15

Gln Ala Ala Lys Glu Phe Ile Ala Trp Leu Val Lys Gly Arg  
20 25 30

<210> 6

<211> 30

<212> PRT

<213> Artificial

<220>

<223> Synthesized Peptide

<220>

<221> MOD\_RES

<222> (30)..(30)

<223> AMIDATION

<400> 6

His Ala Glu Gly Thr Phe Thr Ser Asp Val Ser Ser Tyr Leu Glu Gly  
1 5 10 15

Gln Ala Ala Lys Glu Phe Ile Ala Trp Leu Val Lys Gly Arg  
20 25 30

<210> 7

<211> 39

<212> PRT

<213> Heloderma horridum

<300>

<308> P20394

<309> 2004-06-15

<313> (1)..(39)

<400> 7

His Ser Asp Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Met Glu Glu  
1 5 10 15

Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn Gly Gly Pro Ser  
20 25 30

Ser Gly Ala Pro Pro Pro Ser  
35

<210> 8  
<211> 39  
<212> PRT  
<213> Heloderma suspectum

<300>  
<308> HWGH4G  
<309> 1997-11-21  
<313> (1)..(39)

<400> 8

His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Met Glu Glu  
1 5 10 15

Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn Gly Gly Pro Ser  
20 25 30

Ser Gly Ala Pro Pro Pro Ser  
35

<210> 9  
<211> 31  
<212> PRT  
<213> Artificial

<220>  
<223> Synthesized Peptide

<400> 9

His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Met Glu Glu  
1 5 10 15

Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn Gly Gly Pro Tyr  
20 25 30

<210> 10  
<211> 31  
<212> PRT  
<213> Artificial

<220>  
<223> Synthesized Peptide

<400> 10

Asp Leu Ser Lys Gln Met Glu Glu Glu Ala Val Arg Leu Phe Ile Glu  
1 5 10 15

Trp Leu Lys Asn Gly Gly Pro Ser Ser Gly Ala Pro Pro Pro Ser  
20 25 30

<210> 11  
<211> 34  
<212> PRT  
<213> Artificial

<220>  
<223> Synthesized Peptide

<220>  
<221> MISC\_FEATURE  
<222> (1)..(1)  
<223> Xaa is pyroglutamate

<400> 11

Xaa Leu Gly Pro Gln Gly Pro Pro His Leu Val Ala Asp Pro Ser Lys  
1 5 10 15

Lys Gln Gly Pro Trp Leu Glu Glu Glu Glu Glu Ala Tyr Gly Trp Met  
20 25 30

Asp Phe

<210> 12  
<211> 34  
<212> PRT  
<213> Artificial

<220>  
<223> Synthesized Peptide

<220>  
<221> MISC\_FEATURE  
<222> (1)..(1)  
<223> Xaa is pyroglutamate

<400> 12

Xaa Leu Gly Pro Gln Gly Pro Pro His Leu Val Ala Asp Pro Ser Lys  
1 5 10 15

Lys Gln Gly Pro Trp Leu Glu Glu Glu Glu Glu Ala Tyr Gly Trp Leu  
20 25 30

Asp Phe

<210> 13  
<211> 17  
<212> PRT  
<213> Artificial

<220>  
<223> Synthesized Peptide

<220>  
<221> MISC\_FEATURE  
<222> (1)..(1)  
<223> Xaa is pyroglutamate

<400> 13

Xaa Gly Pro Trp Leu Glu Glu Glu Glu Glu Ala Tyr Gly Trp Met Asp  
1 5 10 15

Phe

<210> 14  
<211> 17  
<212> PRT  
<213> Artificial

<220>  
<223> Synthesized Peptide

<220>  
<221> MISC\_FEATURE  
<222> (1)..(1)  
<223> Xaa is pyroglutamate

<400> 14

Xaa Gly Pro Trp Leu Glu Glu Glu Glu Glu Ala Tyr Gly Trp Leu Asp  
1 5 10 15

Phe

<210> 15  
<211> 101  
<212> PRT  
<213> Artificial

<220>

<223> Synthesized Peptide

<400> 15

Met Gln Arg Leu Cys Val Tyr Val Leu Ile Phe Ala Leu Ala Leu Ala  
1 5 10 15

Ala Phe Ser Glu Ala Ser Trp Lys Pro Arg Ser Gln Gln Pro Asp Ala  
20 25 30

Pro Leu Gly Thr Gly Ala Asn Arg Asp Leu Glu Leu Pro Trp Leu Glu  
35 40 45

Gln Gln Gly Pro Ala Ser His His Arg Arg Gln Leu Gly Pro Gln Gly  
50 55 60

Pro Pro His Leu Val Ala Asp Pro Ser Lys Lys Gln Gly Pro Trp Leu  
65 70 75 80

Glu Glu Glu Glu Glu Ala Tyr Gly Trp Met Asp Phe Gly Arg Arg Ser  
85 90 95

Ala Glu Asp Glu Asn  
100

<210> 16

<211> 52

<212> PRT

<213> Artificial

<220>

<223> Synthesized Peptide

<400> 16

Asp Leu Glu Leu Pro Trp Leu Glu Gln Gln Gly Pro Ala Ser His His  
1 5 10 15

Arg Arg Gln Leu Gly Pro Gln Gly Pro Pro His Leu Val Ala Asp Pro  
20 25 30

Ser Lys Lys Gln Gly Pro Trp Leu Glu Glu Glu Glu Glu Ala Tyr Gly  
35 40 45

Trp Met Asp Phe  
50

<210> 17  
<211> 14  
<212> PRT  
<213> Artificial

<220>  
<223> Synthesized Peptide

<400> 17

Trp Leu Glu Glu Glu Glu Ala Tyr Gly Trp Met Asp Phe  
1 5 10

<210> 18  
<211> 6  
<212> PRT  
<213> Artificial

<220>  
<223> Synthesized Peptide

<400> 18

Tyr Gly Trp Met Asp Phe  
1 5

<210> 19  
<211> 6  
<212> PRT  
<213> Artificial

<220>  
<223> Synthesized Peptide

<400> 19

Tyr Gly Trp Leu Asp Phe  
1 5

<210> 20  
<211> 31  
<212> PRT  
<213> Artificial

<220>  
<223> Synthesized Peptide

<220>  
<221> MISC\_FEATURE  
<222> (31)..(31)  
<223> Xaa is Pro or Tyr



<400> 20

His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Met Glu Glu  
1 5 10 15

Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn Gly Gly Xaa  
20 25 30

<210> 21

<211> 40

<212> PRT

<213> Artificial

<220>

<223> Synthesized Peptide

<220>

<221> MISC\_FEATURE

<222> (2)..(3)

<223> Xaa is Ser or Asp Xaa is Gly or Phe

<400> 21

His Xaa Xaa Gly Thr Phe Ile Thr Ser Asp Leu Ser Lys Gln Met Glu  
1 5 10 15

Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn Gly Gly Pro  
20 25 30

Ser Ser Gly Ala Pro Pro Pro Ser  
35 40

<210> 22

<211> 44

<212> PRT

<213> Artificial

<220>

<223> Synthesized Peptide

<400> 22

His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Met Glu Glu  
1 5 10 15

Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn Gly Gly Pro Ser  
20 25 30

Ser Gly Ala Pro Pro Ser Lys Lys Lys Lys Lys Lys

35

40

<210> 23  
<211> 6  
<212> PRT  
<213> Artificial

<220>  
<223> Synthesized Peptide

<400> 23

Tyr Gly Trp Met Asp Phe  
1 5

<210> 24  
<211> 6  
<212> PRT  
<213> Artificial

<220>  
<223> Synthesized Peptide

<400> 24

Tyr Gly Trp Leu Asp Phe  
1 5

<210> 25  
<211> 10  
<212> PRT  
<213> Artificial

<220>  
<223> Synthesized Peptide

<400> 25

Gly Ala Gly Ala Gly Ala Gly Ala Gly Ala  
1 5 10

<210> 26  
<211> 4  
<212> PRT  
<213> Artificial

<220>  
<223> Synthesized Peptide

<220>  
<221> MOD\_RES  
<222> (4)..(4)

<223> AMIDATION

<400> 26

Trp Met Asp Phe  
1

<210> 27

<211> 4

<212> PRT

<213> Artificial

<220>

<223> Synthesized Peptide

<220>

<221> MOD\_RES

<222> (4)..(4)

<223> AMIDATION

<400> 27

Trp Leu Asp Phe  
1